Jim Cramer's top 10 things to watch in the stock market Monday

The cleaner expression here is still AI infrastructure, but the better risk-adjusted exposure is the “picks-and-shovels of picks-and-shovels” rather than the crowded model layer. If hyperscaler capex stays elevated, NVDA remains the toll collector, while ALAB has more operating leverage to each incremental rack/compute node buildout; that can translate into disproportionate multiple expansion over the next 1-3 months. The key risk is not demand disappearing, but content mix shifting toward cheaper architectures or procurement friction slowing deployment, which would hit ALAB faster than NVDA.

The enterprise-AI / drug-discovery angle is more of a 6-18 month margin story than a near-term P&L driver. For LLY, AI should be viewed as an R&D productivity option that can defend a premium multiple if it shortens cycle times, but it is unlikely to change consensus numbers this year; the market will pay for proof, not press-release partnerships. For ACN, capital returns can cushion EPS, but they do not fix a slower discretionary spending backdrop, so rallies on buyback headlines are vulnerable if clients keep delaying transformation budgets.

PNC looks like the cleaner “quality regional” trade because the bar is now execution rather than survival; if credit stays benign and funding costs ease, the stock can continue to re-rate versus the broader bank basket over the next quarter. YETI is more tactical: restocking can create a short-lived earnings tailwind, but that only matters if sell-through improves, otherwise the channel just refills before another digestion period. Contrarianly, the consensus may be overestimating how quickly AI enthusiasm converts into broad corporate spending, while underestimating how much of the current move is simply factor crowding into semis and away from slower-growth compounders.